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-DTPA and Gd-BOPTA
Kristina I Ringe1,2*, Daniel T Boll2, Daniela B Husarik2, Mustafa R Bashir2, Rajan T Gupta2 and Elmar M Merkle2,3
Abstract
Background: To evaluate the contrast agent performance of Gd-EOB-DTPA and Gd-BOPTA for detection and
assessment of extrahepatic findings, semi-quantitatively and qualitatively.
Methods: 13 patients with 19 extrahepatic lesions underwent liver MRI with Gd-EOB-DTPA and Gd-BOPTA.
Quantitative and relative SNR measurements were performed in each dataset in the arterial and portalvenous phase
within the extrahepatic lesion, aorta, inferior vena cava, portal vein, spleen, pancreas and renal cortex. Further,
relative CNR measurements were performed. Three readers assessed contrast quality using a five-point scale and
choosing the preferred image dataset. Statistical analysis consisted of a Student’s t-test with p < 0.05 deemed
significant, a weighted kappa statistic for assessment of interobserver variability and an ROC analysis.
Results: Mean SNR after injection of Gd-BOPTA was significantly higher compared with Gd-EOB-DTPA for all
measurements (p < 0.05). Mean relative SNR was also higher for Gd-BOPTA, but without being statistically
significant. There was no significant difference in relative CNR. Interobserver agreement for selection of image
preference was moderate (mean weighted kappa 0.485). The area under the curve for the ROC-analysis regarding
contrast agent performance was 0.464.
Conclusion: Even though mean SNR is significantly higher after injection of Gd-BOPTA compared with Gd-EOB
-DTPA, there is no significant difference in relative CNR with extrahepatic lesions being assessed equally well. Visual
impression may differ after injection of Gd-EOB-DTPA, but does not influence image interpretation. Extrahepatic
findings can be assessed similarly to MRI after injection of Gd-BOPTA.
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Background
Gadoxetate disodium (Gd-EOB-DTPA, gadoxetic acid,
EovistW or PrimovistW, Bayer HealthCare, Wayne, NJ) is
a liver-specific contrast agent, which has recently be-
come available for detection and characterization of
focal hepatic lesions. Pharmacokinetic and pharmacody-
namic properties of Gd-EOB-DTPA differ not only from
other non-specific contrast agents used in MR imaging,
but also from more established liver-specific contrast
agents such as Gd-BOPTA (gadobenate dimeglumine,
MultihanceW, Bracco, Princeton, NJ) [1,2].
In contrast to pure extracellular contrast agents, both
substances show a partial specific uptake by hepatocytes
and subsequently biliary excretion, allowing for data ac-
quisition in the hepatocyte phase in addition to the usual
dynamic phases. Whereas hepatic uptake and biliary
elimination for gadobenate dimeglumine is only 3-5%,
excretion through the hepatobiliary pathway is approxi-
mately 50% for gadoxetate disodium [1,3]. In addition,
the characteristic pharmacodynamic properties of Gd-
EOB-DTPA allow a lower dosage compared with other
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gadolinium chelates [4]. A dosage of 0.025 mmol/kg
body weight is approved by the FDA. This dosage is
equivalent to one quarter of the gadolinium dose
recommended for all other MRI contrast agents ap-
proved by the FDA for liver imaging. However, the ap-
proved dosage of 0.025 mmol/kg body weight for
Gd-EOB-DTPA is currently under debate with some ra-
diologists preferring twice that dosage.
Recapitulating, it is known that the distinct pharmaco-
kinetic and pharmacodynamic properties of Gd-EOB
-DTPA may result in a different image appearance espe-
cially of primary and secondary liver lesions [5,6], as well
as other parenchymal organs and vessels [7,8], compared
with other established MRI contrast agents such as Gd-
BOPTA [9]. As comprehensive MR imaging of the liver
usually includes imaging of the upper abdomen, this
leads to the question, whether image interpretation of
incidental extrahepatic findings may be influenced un-
knowingly. It has been suggested that further clinical
studies in patients with various tumors are needed to
clarify this circumstance and to establish more routine
[8]. Thus, the purpose of our study was to evaluate the
contrast agent performance of Gd-EOB-DTPA and Gd-
BOPTA for detection and assessment of extrahepatic
findings both, semi-quantitatively and qualitatively.
Methods
This retrospective study was approved from the local in-
stitutional review board of Duke University Medical
Center with a waiver of consent granted.
Patients
A total of 13 patients (8 male, 5 female; mean age 57.4 -
years, range 37–73 years) were included in this study,
who met the inclusion criteria. The patients were chosen
from a database consisting of a total of 552 patients in
whom MRI was performed including the administration
of Gd-EOB-DTPA at our institution between October
2008 and January 2010. All patients were referred for
liver MR imaging, including administration of a hepato-
cyte specific contrast agent. Due to a change in clinical
routine patients received different contrast agents over
time and for clinical follow-up. Inclusion criteria were as
follows: age of at least 18 years, availability of a compari-
son study within one year and administration of either
Gd-EOB-DTPA or Gd-BOPTA, and presence of an ex-
trahepatic finding seen on both imaging studies.
The extrahepatic lesions were as follows: 4 adrenal le-
sions (adenoma n = 3, metastasis n = 1), 5 kidney lesions
(angiomyolipoma n = 1, metastasis n = 4), 5 splenic le-
sions (hemangioma n = 5), 2 pulmonary lesions
(hamartoma n = 2), 1 pancreatic lesion (microcystic
cystadenoma n = 1), 2 spinal lesions (metastasis n = 2).
Parenchymal lesions showed no change in size (mean
lesion size: 2.15 cm; range: 1–4.32 cm) and appearance
between comparative studies. Patient characteristics are
summarized in Table 1.
MR imaging technique
MR examinations were all performed on 1.5 T systems.
Including the administration of Gd-EOB-DTPA exami-
nations were performed on following scanners:
Magnetom Avanto (Siemens, Erlangen, Germany), n = 5;
Signa HDx (GE Healthcare, Milwaukee, USA), n = 8.
Comparison studies including the administration of Gd-
BOPTA were performed on the same scanners
(Magnetom Avanto; Siemens (n = 5) or Signa HDx; GE
Healthcare (n = 8)).
In all patients, dedicated multidetector surface coils
that covered the abdomen were used. All patients under-
went a clinical routine image protocol of the liver in-
cluding the administration of either 0.025 mmol/ kg Gd-
EOB-DTPA or 0.1 mL/ kg Gd-BOPTA at a rate of
2 mL/ sec followed by a saline flush using a dual power
injector. The MR pulse sequence protocol for all exami-
nations included a T2w HASTE (half-Fourier single shot
turbo spin-echo) and a T1w gradient dual echo sequence
before contrast injection, as well as a dynamic contrast
series including the acquisition of a triple arterial phase
(3D T1w gradient echo sequence) with a fixed scan delay
(15 seconds in patients <60 years and 20 seconds in pa-
tients >60 years, respectively) and a portal venous phase
(3D T1w gradient echo sequence) after contrast injec-
tion, which was acquired approximately 15–20 seconds
after completion after the arterial phase data acquisition.
These imaging sequences and parameters were the same
between imaging platforms and comparative studies.
Image evaluation
a. Quantitative analysis: In each patient signal-to-noise
ratio (SNR; signal intensity / standard deviation
Table 1 Patient characteristics and assessed extrahepatic
findings
Gender (male / female) 8 / 5
Age (years) 37-73 (mean 57.4)
Extrahepatic lesion
Adrenal adenoma 3
Adrenal metastasis 1
Angiomyolipoma kidney 1
Kidney metastasis 4
Splenic hemangioma 5
Pulmonary hamartoma 2
Pancreatic cystadenoma 1
Spinal metastasis 2
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noise) measurements were obtained in each dataset
(Gd-EOB-DTPA and Gd-BOPTA) in the arterial and
portal venous phase in corresponding positions.
Noise estimates were derived in each dataset from a
region outside the body in the vicinity of the liver.
Measurements were all conducted by two
radiologists in consensus (KIR, fifth year radiology
resident and EMM, fellowship-trained radiologist
with a focus on abdominal imaging and 13 years of
experience after board certification) who where
blinded to the type of dataset. By placing an oval
region of interest (ROI) measurements were
performed in the aorta, inferior vena cava, portal
vein, pancreas, spleen, renal cortex and the
extrahepatic lesion. The size of the ROI was adjusted
to the size of the lesion and the same for
comparative studies. In addition, relative SNR ((SNR
post contrast - SNR pre contrast) / SNR pre contrast) and
relative contrast to noise (CNR; relative SNR lesion -
relative SNR organ) measurements were obtained in
the same position of each dataset and examination.
b. Qualitative analysis: Of each dataset (Gd-EOB-
DTPA and Gd-BOPTA) representative T1w non
contrast, arterial and portal venous phase images
were prepared for blinded reading and opposed for
comparison (dataset A and dataset B). Three
independent readers performed the qualitative image
analysis in terms of assessing lesion detectability and
contrast quality using a five-point scale: 1, non
diagnostic; 2, poor; 3, acceptable; 4, good; 5, very
good. The group of readers comprised a junior
abdominal imaging attending one year post
fellowship training (RTG), an abdominal imaging
fellow (MRB) and a fifth year radiology resident
(DBH). In addition, each reader was asked to choose
the preferred imaging dataset.
c. Statistical analysis: Statistical analysis was performed
with SPSS software (version 17; SPSS, Chicago,
Illinois). Results of the quantitative analyses were
compared with a two-sided unpaired student’s T-test,
with p < 0.05 deemed significant. Interobserver
variability was assessed by means of a weighted kappa
statistic and an ROC analysis. Interobserver
agreement was classified as follows: a κ value of less
than 0.20 indicated poor agreement; a κ value of 0.21-
0.40, fair agreement; a κ value of 0.41-0.60, moderate
agreement; a κ value of 0.61-0.80, good agreement; a κ
value of 0.81-1.00, excellent agreement [10].
Results
All patients underwent MR imaging of the upper abdo-
men using Gd-BOPTA and Gd-EOB-DTPA. Mean time
interval between both examinations was 165 days (range
23–265 days).
a. Quantitative analysis: Mean SNR after injection of Gd-
BOPTA was significantly higher compared with Gd-
EOB-DTPA for all lesions, vessels and organs, in the
arterial as well as in the portal venous phase (p < 0.05)
(Figures 1, 2). Mean SNR for assessed lesions in the
arterial phase was 266.7 (range 50–528) for Gd-EOB
-DTPA and 567.5 (range 52–1956) for Gd-BOPTA,
respectively. Mean SNR for evaluated lesions in the
portal venous phase was 221.4 (range 72–428) for Gd-
EOB-DTPA and 617.6 (range 88–2502) for Gd-
BOPTA, respectively. Mean relative SNR was also
higher for Gd-BOPTA, but without being statistically
significant (e.g. mean relative SNR for assessed lesions
in the arterial phase was 0.9 (range 0.1-3.3) for Gd-
EOB-DTPA and 1.0 (range 0.1-3,8) for Gd-BOPTA;
mean relative SNR for evaluated lesions in the portal
venous phase was 0.6 (range 0.1-2.4) for Gd-EOB
-DTPA and 1.1 (range 0.1-4,5) for Gd-BOPTA,
respectively). For all measurements there was no
significant difference in relative CNR, neither in the
arterial nor in the portal venous phase (p > 0.05).
b. Qualitative analysis: For all readers there were no
significant differences in image quality comparing
imaging with Gd-BOPTA and Gd-EOB-DTPA
(Figure 3). Interobserver variability regarding the
assessment of image quality was fair for Gd-EOB
-DTPA and Gd-BOPTA with a mean weighted
kappa of 0.245 and 0.316, respectively. Interobserver
agreement for selection of image preference was
moderate (mean weighted kappa 0.485). The area
under the curve for the ROC-analysis was 0.464,
implying that there was no significant difference
comparing imaging with Gd-EOB-DTPA and Gd-
BOPTA.
Discussion
Extracellular contrast agents, such as gadopentetate
dimeglumine (Gd-DTPA, Magnevist, Bayer HealthCare),
have been in clinical use for more than two decades and
are well established. More recently, liver-specific con-
trast agents have become available for the detection and
characterization of focal hepatic lesions. Whereas Gd-
BOPTA has been approved for liver imaging by the
European authorities several years ago and certain ex-
perience and routine is available, Gd-EOB-DTPA is fairly
new and has gained FDA approval only in 2008.
Brismar et al. compared liver vessel and liver paren-
chymal enhancement after the injection of Gd-EOB
-DTPA and Gd-BOPTA using a bolus technique in ten
healthy volunteers. Results showed a higher maximum
of enhancement of the hepatic artery, portal vein and
middle hepatic vein during the arterial, portal venous
phase and delayed phase for Gd-BOPTA, while there
was no significant difference in liver parenchymal
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contrast enhancement [7]. So far only few studies have
compared the performance of Gd-EOB-DTPA with
other more established contrast agents regarding the as-
sessment of extrahepatic tissues and vessels. Kühn et al.
compared the enhancement patterns of solid organs and
the abdominal aorta after the injection of gadobutrol
and gadoxetate disodium in 50 patients. Mean enhance-
ment indexes were higher for gadobutrol except for the
abdominal aorta, and it has been suggested that early dy-
namic MRI of the upper abdomen benefits from the
higher gadolinium concentration of gadobutrol than in
the organ-specific contrast agent gadoxetic acid [11].
However, patients in the two compared contrast agents
groups were not the same. These results were similar to
those gained by Zizka et al. earlier [12]. A more recent
intraindividual comparison of liver, abdominal and pul-
monary vessel enhancement in staging for rectal carcin-
oma showed comparable contrast enhancement after
gadoxetic acid to gadobutrol [13]. Tamada et al. com-
pared enhancement patterns of solid abdominal organs
and vessels in 13 healthy volunteers after the injection of
Gd-DTPA (Magnevist) and Gd-EOB-DTPA. It has been
proposed that lower arterial vascular and parenchymal
enhancement with Gd-EOB-DTPA as compared with
Figure 1 Comparison of SNR measurements using Gd-EOB-DTPA (Eovist→, Bayer HealthCare, Wayne, NJ) and Gd-BOPTA (Multihance→,
Bracco, Princeton, NJ) in the arterial phase. Shown is the mean SNR for the extrahepatic lesion, as well as for different vessels and organs.
Figure 2 Comparison of SNR measurements using Gd-EOB-DTPA (Eovist→, Bayer HealthCare, Wayne, NJ) and Gd-BOPTA (Multihance→,
Bracco, Princeton, NJ) in the portal venous phase. Shown is the mean SNR for the extrahepatic lesion, as well as for different vessels
and organs.
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GD-DTPA may require reassessment of its dose, despite
the higher late venous phase liver parenchymal enhance-
ment [8].
To the best of our knowledge, no study has so far
compared the enhancement effect of extrahepatic find-
ings in MR imaging with Gd-EOB-DTPA and Gd-
BOPTA. Our results show that even though mean SNR
in extrahepatic lesions, vessels and organs is significantly
higher after the injection of Gd-BOPTA compared with
Gd-EOB-DTPA, there is no significant difference in rela-
tive CNR with extrahepatic lesions being assessed ad-
equately. Thus, visual impression may differ after
injection of Gd-EOB-DTPA, but does not influence
image interpretation, and extrahepatic findings can be
assessed similarly to MRI after injection of Gd-BOPTA.
The circumstance that interobserver variability for Gd-
BOPTA is slightly better than for Gd-EOB-DTPA may
be justified to some extent by the fact, that gadoxetate
disodium is a relatively new contrast agent resulting in a
different image impression and that we are in the
process of gaining more routine [5-8].
Our study has a number of limitations. The time inter-
val between MRI examination with Gd-EOB-DTPA and
Gd-BOPTA was fairly long in some patients (mean 165 -
days). On the other hand, evaluated parenchymal lesions
showed no change in size and appearance between com-
parative studies, so that evaluation especially of meta-
static lesions could not be influenced by these factors.
Figure 3 Comparison of Gd-BOPTA (A-C) and Gd-EOB-DTPA (D-E) for detection and characterization of a splenic hemangioma. Pre
contrast T1w images (A,D; top row), arterial phase images (B,E; middle row) and portal venous phase images (C,F; bottom row).
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Also, comparative studies were performed on the same
scanners using identical imaging parameters. Another
limitation is the small sample size and heterogeneity of
incidentally detected lesions (malignant as well as be-
nign). As the same lesion was evaluated on two different
studies, we think that this intralesional comparison is
valid.
Conclusions
In conclusion, hepatocyte-specific contrast agents are in-
creasingly used for comprehensive MR imaging of the
liver. Incidental extrahepatic parenchymal findings are
common and need to be appraised when imaged. It is
known that the distinct pharmacokinetic and pharmaco-
dynamic properties of Gd-EOB-DTPA may result in a
different image appearance especially of primary and
secondary liver lesions. Therefore assessment of extrahe-
patic findings may unknowingly be influenced as well,
and a comparison of contrast agent performance is clin-
ically important. The results of our study show, that vis-
ual impression of incidental extrahepatic findings may
differ after injection of Gd-EOB-DTPA compared with
Gd-BOPTA, but does not influence image interpretation.
Reliable assessment of extrahepatic findings is feasible
using the hepatocyte-specific contrast agent Gd-EOB
-DTPA, although results need to be validated in future
studies with larger patient cohorts.
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